236 related articles for article (PubMed ID: 15894946)
1. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
[TBL] [Abstract][Full Text] [Related]
2. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
Tonkon M; Awan N; Niazi I; Hanley P; Baruch L; Wolf RA; Block AJ
Int J Clin Pract; 2000; 54(1):11-4, 16-8. PubMed ID: 10750252
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Dickstein K; Chang P; Willenheimer R; Haunsø S; Remes J; Hall C; Kjekshus J
J Am Coll Cardiol; 1995 Aug; 26(2):438-45. PubMed ID: 7608448
[TBL] [Abstract][Full Text] [Related]
4. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
[TBL] [Abstract][Full Text] [Related]
6. Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
Blanchet M; Ducharme A; Racine N; Rouleau JL; Tardif JC; Juneau M; Marquis J; Larivée L; Nigam A; Fortier A; White M
Am J Cardiol; 2003 Sep; 92(5):548-53. PubMed ID: 12943875
[TBL] [Abstract][Full Text] [Related]
7. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
[TBL] [Abstract][Full Text] [Related]
8. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
Jorde UP; Vittorio TJ; Dimayuga CA; Homma S; Rizkala A; Le Jemtel TH; Katz SD
Am J Cardiol; 2004 Dec; 94(12):1501-5. PubMed ID: 15589004
[TBL] [Abstract][Full Text] [Related]
9. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
Kum LC; Yip GW; Lee PW; Lam YY; Wu EB; Chan AK; Fung JW; Chan JY; Zhang Q; Kong SL; Yu CM
Int J Cardiol; 2008 Mar; 125(1):16-21. PubMed ID: 17433840
[TBL] [Abstract][Full Text] [Related]
10. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Yasumura Y; Miyatake K; Okamoto H; Miyauchi T; Kawana M; Tsutamoto T; Kitakaze M; Matsubara H; Takaoka H; Anzai T; Himeno H; Yokoyama H; Yokoya K; Shintani U; Hashimoto K; Koretsune Y; Nakamura Y; Imai K; Maruyama S; Masaoka Y; Sekiya M; Shiraki T; Shinohara H; Ozono K; Matsuoka T; Miyao Y; Nomura F
Circ J; 2004 Apr; 68(4):361-6. PubMed ID: 15056835
[TBL] [Abstract][Full Text] [Related]
12. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.
Dunselman PH;
Int J Cardiol; 2001 Feb; 77(2-3):131-8; discussion 139-40. PubMed ID: 11182175
[TBL] [Abstract][Full Text] [Related]
13. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
[TBL] [Abstract][Full Text] [Related]
14. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Sigurdsson A
Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
[TBL] [Abstract][Full Text] [Related]
15. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
16. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E
Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
19. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Tsuyuki RT; Yusuf S; Rouleau JL; Maggioni AP; McKelvie RS; Wiecek EM; Wang Y; Pogue J; Teo KK; White M; Avezum A; Latini R; Held P; Lindgren E; Probstfield J
Can J Cardiol; 1997 Dec; 13(12):1166-74. PubMed ID: 9444298
[TBL] [Abstract][Full Text] [Related]
20. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
Ellis GR; Nightingale AK; Blackman DJ; Anderson RA; Mumford C; Timmins G; Lang D; Jackson SK; Penney MD; Lewis MJ; Frenneaux MP; Morris-Thurgood J
Eur J Heart Fail; 2002 Mar; 4(2):193-9. PubMed ID: 11959049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
